Case Reports
doi: 10.1097/JTO.0000000000000197.
Coexistence of tyrosine kinase inhibitor-sensitizing and resistant EGFR mutations in an untreated lung adenocarcinoma patient and response to erlotinib
Affiliations
- PMID: 24926557
- DOI: 10.1097/JTO.0000000000000197
Item in Clipboard
Case Reports
Coexistence of tyrosine kinase inhibitor-sensitizing and resistant EGFR mutations in an untreated lung adenocarcinoma patient and response to erlotinib
J Thorac Oncol.
2014 Jul.
Free article
No abstract available
Similar articles
-
Retreatment with erlotinib of a patient with metastatic NSCLC harboring EGFR mutation: a case report.Tumori. 2014 May-Jun;100(3):e70-3. doi: 10.1700/1578.17234. Tumori. 2014. PMID: 25076254
-
De novo ERBB2 amplification causing intrinsic resistance to erlotinib in EGFR-L858R mutated TKI-naïve lung adenocarcinoma.Lung Cancer. 2017 Dec;114:108-110. doi: 10.1016/j.lungcan.2017.08.018. Epub 2017 Aug 24. Lung Cancer. 2017. PMID: 28870636 No abstract available.
-
A Phase II Study of Poziotinib in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Lung Adenocarcinoma Who Have Acquired Resistance to EGFR-Tyrosine Kinase Inhibitors.Cancer Res Treat. 2017 Jan;49(1):10-19. doi: 10.4143/crt.2016.058. Epub 2016 May 3. Cancer Res Treat. 2017. PMID: 27188206 Free PMC article. Clinical Trial.
-
Lung adenocarcinoma harboring concomitant EGFR mutation and EML4-ALK fusion that benefits from three kinds of tyrosine kinase inhibitors: a case report and literature review.Clin Lung Cancer. 2015 Mar;16(2):e5-9. doi: 10.1016/j.cllc.2014.11.001. Epub 2014 Nov 18. Clin Lung Cancer. 2015. PMID: 25496960 Review. No abstract available.
-
Targeted therapy: an evolving world of lung cancer.Respirology. 2011 Jan;16(1):13-21. doi: 10.1111/j.1440-1843.2010.01821.x. Epub 2010 Aug 16. Respirology. 2011. PMID: 20723139 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous
